

The MMRF is dedicated to finding innovative ways to fight cancer.



Before the MMRF, there were no new treatments for decades. Today, with the most respected research, pharma, medical, and technology partners, patients have benefitted tremendously because the MMRF has fueled more studies, initiated more trials, developed more treatments, and introduced more medicines than any other cancer research foundation. There have been 10 approved treatments in just over a decade and life expectancy has tripled. The MMRF has changed the paradigm of cancer research and continues to drive results in ways unseen in any disease.

THE DATA BANK

Data generation & integration



MMGI
CoMMpass
Registry

THE LEARNING NETWORK

Collaboration & discovery



Gateways
Myeloma Disease Model
Translational Network

THE CLINIC

Accelerating trials



MMRC

- Molecularly targeted therapies
- Immune therapies
- Novel therapies

We have built an end-to-end system in precision medicine that generates, centralizes and analyzes large amounts of top quality clinical and molecular data, encourages the open sharing of data by pushing it into the public domain, and accelerates clinical trials to make treatments available faster.

We are working in partnership with today's leading companies, researchers, doctors, and technology to develop molecularly targeted, immune, and novel therapies, to get the right treatment to the right patient, at the right time.

- 1998 MMRF established
- 2002 Zometa® approved
- 2003 Velcade® approved
- 2004 MMRC founded
- 2004 MMRF tissue bank established
- 2006 Thalomid® approved
- 2007 Revlimid® approved
- 2008 Doxil® approved
- 2011 MMRF CoMMpassSM Study launched
- 2011 Record eight treatments in Phase III trials
- 2012 Kyprolis® approved
- 2013 Pomalyst® approved
- 2013 CoMMunity and Researcher Gateways launched

Our mission is to accelerate cures and save lives.

Because the MMRF was founded by a patient, our system was built around the patient. It is the reason we are able to deliver better results, faster and more efficiently.

We run our business with the same efficiency that we expect of our partners and the whole of the medical community. We feel it is our responsibility to set an example and run our business driven by efficiency and results. We consistently outperform our peers in fiscal responsibility, accountability, and transparency. We direct nearly 90% of our total budget to research and related programming. Our founder, Kathy Giusti has been recognized by *Time Magazine* as one of the top 100 most influential people in the world, by *Fortune Magazine* as one of the world's 50 greatest leaders, and appointed to the White House Precision Medicine Initiative.

We are curing cancer now.

- 2014 MMRC launches 50th clinical trial
- 2015 Farydak® approved
- 2015 Darzalex™ approved
- 2015 CoMMpass Study enrolls 1,000th patient
- 2015 Ninlaro® approved
- 2015 Emplificiti® approved
- More Treatments
- Longer Lifespan
- FINDING CURES**

OUR PARTNERS' OBSERVATIONS



Eric Lander PhD
President, Founding Director
Broad Institute of MIT and Harvard

With the MMRF, we will accelerate many of the traditional steps in the drug discovery and development process, and bypass obstacles that delay or prevent promising treatments from reaching patients.



William H. Hait MD, PhD
Global Head, Research and Development, Janssen

Progress is happening so fast in multiple myeloma research because the MMRF is driving everyone to work together toward a common goal. It should be happening in every cancer.



Colin Hill BS, MS, CEO
Chairman and co-founder of GNS Healthcare

The MMRF model fuels early stage disease investigation and the development of powerful molecular and immunological tools to bring us one step closer to eliminating the disease altogether.

